{"url_path":"/sec/avtx/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000032-index.html","accession_number":"0001534120-26-000032","cik":"0001534120","ticker":"AVTX","issuer_name":"Avalo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000032-index.html","primary_entity_key":"0001534120","primary_entity_name":"Avalo Therapeutics, Inc."},"word_count":116,"has_tables":true,"body_markdown":"Item 2.02    Results of Operations and Financial Condition.\n\nOn May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1.\n\nInformation in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}